In its first transaction of the year, GSK Plc, announced that it acquired Rapt Therapeutics, Inc. for $58 per share. That price equates to an aggregate equity value of $2.2 billion, according to GSK, which added that the upfront investment net of cash acquired comes to $1.9 billion. Net of cash acquired, […]
The post GSK Acquires Rapt Therapeutics For $2.2 Billion appeared first on LevinPro Healthcare M&A – The latest healthcare M&A news.
